Vanda's VCA-894A Receives FDA Rare Pediatric Designation, Potential for Priority Review Voucher
VNDA sits 56% above its 52-week low of $4.14.
Summary
Vanda Pharmaceuticals received FDA Rare Pediatric Disease Designation for VCA-894A, an investigational therapy for the ultra-rare Charcot-Marie-Tooth disease type 2S, which is a neurological disorder. This designation is significant as it makes the program eligible for a Priority Review Voucher (PRV) upon potential future approval. A PRV could be a valuable asset, potentially worth hundreds of millions, which is material for Vanda given its current market capitalization and recent Q1 report showing increased net losses and substantial cash burn. This provides a potential non-dilutive funding source for the company's pipeline.
At the time of this announcement, VNDA was trading at $6.46 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $384.3M. The 52-week trading range was $4.14 to $9.94. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.